• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed by Allena Pharmaceuticals Inc.

    9/14/22 9:52:49 AM ET
    $ALNA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALNA alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-38268
    Issuer: Allena Pharmaceuticals, Inc.
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 142-F North Road, Suite 150
    Sudbury MASSACHUSETTS 01776
    Telephone number: 617-467-4577
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    Common Stock
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2022-09-14 By Aravind Menon Hearings Advisor
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $ALNA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ALNA

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $ALNA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Allena Pharmaceuticals Announces Completion of Enrollment of Cohorts A and B of ALLN-346 Phase 2a Study 202 in Patients with Gout and Stages 2 and 3 Chronic Kidney Disease

      NEWTON, Mass., July 19, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA) ("Allena" or the "Company"), a biopharmaceutical company deploying its novel oral biologic platform to discover, develop and commercialize first-in-class, oral enzyme therapeutics for difficult-to treat metabolic diseases, today reported completion of enrollment of the first two cohorts of its ALLN-346 Phase 2a Study 202 in gout patients with stage 2 (cohort A) and stage 3 (cohort B) chronic kidney disease (CKD). ALLN-346, which has received Fast Track Designation from the U.S. Food and Drug Administration (FDA), is a first-in-class, non-absorbed, orally administered enzyme in development for the tr

      7/19/22 8:00:00 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock Split

      NEWTON, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has rescheduled its special meeting to, among other things, consider and vote on a proposed amendment to its amended and restated certificate of incorporation, as amended, in order to effect a reverse stock split of its issued and outstanding common stock. The Special Meeting will now be held on August 4, 2022, at 9:00 a.m., local time via live webcast. The new record date for the

      7/12/22 4:05:00 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Announces Rescheduling of Special Meeting to Approve Reverse Stock Split

      NEWTON, Mass., July 05, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has rescheduled its special meeting, which was scheduled for July 5, 2022, to, among other things, consider and vote on a proposed amendment to its amended and restated certificate of incorporation, as amended, in order to effect a reverse stock split of its issued and outstanding common stock. The date of the rescheduled special meeting, and the new record date for determining the

      7/5/22 7:00:00 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Katz Richard D

      4 - Allena Pharmaceuticals, Inc. (0001624658) (Issuer)

      2/2/22 4:15:22 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Brenner Louis Md

      4 - Allena Pharmaceuticals, Inc. (0001624658) (Issuer)

      2/2/22 4:15:11 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4: Brenner Louis Md sold $32,666 worth of shares (40,328 units at $0.81) and converted options into 125,582 shares (tax withholding)

      4 - Allena Pharmaceuticals, Inc. (0001624658) (Issuer)

      11/17/21 5:00:29 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNA
    Financials

    Live finance-specific insights

    See more
    • Allena Pharmaceuticals Provides Clinical and Corporate Update

      ALLN-346, an orally administered enzyme in development for the treatment of hyperuricemia and gout, demonstrates a statistically significant reduction in serum uric acid and a well-tolerated safety profile in first cohort of patients with hyperuricemia and chronic kidney disease in the Phase 2a Study 201 Allena to host webinar to discuss the initial Study 201 data with Key Opinion Leaders Robert Terkeltaub, M.D. and David S. Goldfarb, M.D. today at 8:00 am ET; log-in information belowALLN-346 Phase 2a Study 202 is actively enrolling patients with gout and stages 2 and 3 chronic kidney disease in parallel cohorts; data from both cohorts expected in Q1 2022Company currently evaluating potenti

      1/4/22 5:00:00 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Increases Previously Announced Bought Deal to $13.0 Million

      NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced today that, due to demand, the underwriter has agreed to increase the size of the previously announced public offering and purchase on a firm commitment basis 10,400,000 shares of common stock of the Company, at a price to the public of $1.25 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about December 4, 2020, subject to satisfact

      12/1/20 9:47:45 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Announces $10.0 Million Bought Deal Offering

      NEWTON, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, announced today that it has entered into an underwriting agreement with H.C. Wainwright & Co., LLC under which the underwriter has agreed to purchase on a firm commitment basis 8,000,000 shares of common stock of the Company, at a price to the public of $1.25 per share, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about December 4, 2020, subject to sa

      12/1/20 5:00:00 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Allena Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Allena Pharmaceuticals, Inc. (0001624658) (Subject)

      2/14/23 4:09:01 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Allena Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Allena Pharmaceuticals, Inc. (0001624658) (Subject)

      2/14/22 4:34:57 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Allena Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Allena Pharmaceuticals, Inc. (0001624658) (Subject)

      1/28/22 1:42:29 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNA
    SEC Filings

    See more
    • SEC Form SEC STAFF ACTION filed by Allena Pharmaceuticals Inc.

      SEC STAFF ACTION - Allena Pharmaceuticals, Inc. (0001624658) (Filer)

      6/12/23 2:00:02 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form NT 10-Q filed by Allena Pharmaceuticals Inc.

      NT 10-Q - Allena Pharmaceuticals, Inc. (0001624658) (Filer)

      11/14/22 4:03:10 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 25-NSE filed by Allena Pharmaceuticals Inc.

      25-NSE - Allena Pharmaceuticals, Inc. (0001624658) (Subject)

      9/14/22 9:52:49 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ALNA
    Leadership Updates

    Live Leadership Updates

    See more
    • Allena Pharmaceuticals Announces New Meeting Date and New Record Date for Special Meeting to Approve Reverse Stock Split

      NEWTON, Mass., July 12, 2022 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ:ALNA), a late-stage, biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced that it has rescheduled its special meeting to, among other things, consider and vote on a proposed amendment to its amended and restated certificate of incorporation, as amended, in order to effect a reverse stock split of its issued and outstanding common stock. The Special Meeting will now be held on August 4, 2022, at 9:00 a.m., local time via live webcast. The new record date for the

      7/12/22 4:05:00 PM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Versantis Appoints Mark Fitzpatrick, Seasoned Biotech Executive, as its New CEO

      - Versantis establishes wholly-owned U.S. subsidiary, Versantis, Inc. - - Current CEO, Vincent Forster, to maintain his key role as Chief Scientific Officer - Versantis, a clinical-stage biotechnology company developing novel therapies for orphan liver and pediatric diseases, today announced the appointment of Mark J. Fitzpatrick as Chief Executive Officer (CEO) and member of the board of directors, effective January 1, 2022. He joins Versantis with more than 25 years of experience in the biopharma industry, primarily in senior executive roles, and will be based in the U.S. following the establishment of Versantis, Inc. He succeeds co-founder Dr. Vincent Forster, who will assume the role

      12/20/21 1:00:00 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Allena Pharmaceuticals Appoints Mark J. Fitzpatrick to its Board of Directors Allena Pharmaceuticals, Inc.

      NEWTON, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Allena Pharmaceuticals, Inc. (NASDAQ: ALNA), a late-stage biopharmaceutical company dedicated to developing and commercializing first-in-class, oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders, today announced the appointment of Mark J. Fitzpatrick to its board of directors. “Mark is an experienced industry executive, who has led financial strategy at biopharmaceutical companies across all stages of development,” said Louis Brenner, M.D., President and Chief Executive Officer of Allena Pharmaceuticals. “His extensive experience working with late-stage, rare disease companies will be particular

      4/7/21 8:00:00 AM ET
      $ALNA
      Biotechnology: Pharmaceutical Preparations
      Health Care